Related Experiment Video
Updated: Sep 25, 2025

A Platform of Anti-biofilm Assays Suited to the Exploration of Natural Compound Libraries
Published on: December 27, 2016
Penicillin G concentrations required for prophylaxis against Group A Streptococcus infection evaluated using a hollow
Jessica R Tait1, Timothy C Barnett2, Kate E Rogers1
1Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Background:
Acute rheumatic fever (ARF), an autoimmune reaction to Group A Streptococcus (Streptococcus pyogenes; Strep A) infection, can cause rheumatic heart disease (RHD). New formulations of long-acting penicillins are being developed for secondary prophylaxis of ARF and RHD.
Objectives:
To evaluate the penicillin G concentrations required to suppress growth of Strep A.
Methods:
Broth microdilution MIC and MBC for Strep A strains M75611024, M1T15448 and M18MGAS8232 were determined. All strains were studied in a hollow fibre model (initial inoculum 4 log10 cfu/mL). Constant penicillin G concentrations of 0.008, 0.016 and 0.05 mg/L were examined against all strains, plus 0.012 mg/L against M18MGAS8232. Viable counts were determined over 144 h. Subsequently, all penicillin G-treated cartridges were emptied, reinoculated with 5 log10 cfu/mL and counts determined over a further 144 h. Mathematical modelling was performed.
Results:
MIC and MBC were 0.008 mg/L for all strains; small subpopulations of M75611024 and M1T15448, but not M18MGAS8232, grew at 1× MIC. Following the first inoculation, 0.008 mg/L achieved limited killing and/or stasis against M75611024 and M1T15448, with subsequent growth to ∼6 log10 cfu/mL. Following both inocula, concentrations ≥0.016 mg/L suppressed M75611024 and M1T15448 to <1 log10 cfu/mL from 6 h onwards with eradication. Concentrations ≥0.008 mg/L suppressed M18MGAS8232 to <1 log10 cfu/mL from 24 h onwards with eradication after both inoculations. Mathematical modelling well described all strains using a single set of parameter estimates, except for different maximum bacterial concentrations and proportions of bacteria growing at 1× MIC.
Conclusions:
In the absence of validated animal and human challenge models, the study provides guidance on penicillin G target concentrations for development of new penicillin formulations.
Insights
New penicillin formulations aim to prevent acute rheumatic fever (ARF) and rheumatic heart disease (RHD). Penicillin G concentrations of at least 0.016 mg/L are needed to suppress Group A Streptococcus growth effectively.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) stem from Group A Streptococcus (Strep A) infections.
- New long-acting penicillin formulations are being developed for ARF and RHD secondary prophylaxis.
Purpose of the Study:
- To determine the necessary penicillin G concentrations for inhibiting Strep A growth.
- To inform the development of novel penicillin formulations for ARF and RHD prevention.
Main Methods:
- Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) assays for Strep A strains.
- Hollow fiber model simulating in vivo conditions with varying penicillin G concentrations.
- Mathematical modeling to analyze bacterial growth and eradication dynamics.
Main Results:
- MIC and MBC for all tested Strep A strains were 0.008 mg/L.
- Penicillin G concentrations ≥0.016 mg/L eradicated Strep A (M75611024, M1T15448) within 6 hours.
- Lower concentrations (≥0.008 mg/L) eradicated Strep A (M18MGAS8232) within 24 hours.
Conclusions:
- The study provides crucial data on penicillin G target concentrations for new ARF/RHD prophylactic agents.
- Findings guide the development of effective long-acting penicillin formulations.
- This research aids in combating ARF and RHD, particularly in vulnerable populations.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
07:16Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
Published on: September 20, 2024